2,188
Participants
Start Date
February 20, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
No intervention
No intervention was implemented.
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli)
The bivalent HPV-16/18 vaccine was a mixture of two aluminum hydroxide adjuvant-absorbed recombinant L1 VLPs of HPV-16 and HPV-18 expressed in E. coli. A 0.5 ml dose of the bivalent HPV test vaccine comprised 40 μg of HPV-16 and 20 μg of HPV-18 L1 VLPs absorbed with 208 μg of aluminum adjuvant.
Sheyang County Center for Disease Control and Prevention, Yancheng
Xiamen Innovax Biotech Co., Ltd
INDUSTRY
Center for Disease Control and Prevention, Sheyang County, Yancheng City, Jiangsu Province, China
UNKNOWN
Xiamen University
OTHER